1. History, diagnosis, and epidemiology
1: David L. Scott: The history of rheumatoid arthritis
2: Daniel Aletaha and Helga Radner: Diagnosis
3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology of rheumatoid arthritis
4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk factors for rheumatoid arthritis: a basis for prevention and better therapy
2. Pathogenesis
5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis
6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris Buckley: Dysregulation of synovial fibroblasts in rheumatoid arthritis
7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis
8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas: Dendritic cells and T cells in rheumatoid arthritis
9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage destruction
10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other mediators
3. Clinical presentation
11: Annette van der Helm-van Mil: Clinical features of rheumatoid arthritis
12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg: Pre-rheumatoid arthritis
13: Katherine MacDonald, Jennifer Hannah, and James Galloway: Non-articular manifestations of rheumatoid arthritis
14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid arthritis
4. Disease assessment
15: Josef Smolen: Disease activity assessment in rheumatoid arthritis
16: Douglas Veale and Ursula Fearon: Synovial biopsies
17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: Radiography in rheumatoid arthritis
18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin: Ultrasound in rheumatoid arthritis
19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in rheumatoid arthritis
5. Impact on life
20: Kathryn A. Gibson and Theodore Pincus: Patient physical function in rheumatoid arthritis
21: Emma Dures and Neil Basu: Fatigue
22: David L. Scott and Allan Wailoo: Health economics
23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway: Rheumatoid arthritis and work
6. Non-drug treatments
24: Lindsay Bearne and Christina Opava: Exercise
25: Heidi Siddle and Anthony Redmond: Foot health
26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational therapy
27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective
7. Drug treatments
28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs
29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J. Bijlsma, and José A. P. da Silva: Glucocorticoids
30: David L. Scott: Conventional disease modifying drugs
31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors
32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors
33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies
34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars
35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in response to biologic agents
36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK inhibitors in the treatment of rheumatoid arthritis
37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler: Combination therapy in rheumatoid arthritis
38: Jeremy Sokolove: Translation of new therapies: from bench to bedside
39: James Galloway and Mark Yates: Adverse events in clinical studies in rheumatoid arthritis
8. Management and outcomes
40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope: Prevention of rheumatoid arthritis
41: Kenneth F Baker and Arthur G Pratt: Treatment targets and remission
42: David L. Scott: Clinical outcomes
43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien: Clinical guidelines
44: Angela Zink and Anja Strangfeld: European biologics registers
45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries
